3-F-BPAP

3-F-BPAP is a trifluorinated derivative of benzofuranylpropylaminopentane and is an antagonist of the monoaminergic activity enhancer effects of the tryptamine-related BPAP.
Conversely, 3-F-BPAP does not antagonize the catecholaminergic activity enhancer effects of the phenethylamine-derived selegiline and phenylpropylaminopentane. This suggests that different MAEs like BPAP and selegiline may not be identical in their actions and might be acting via different receptor subtypes. In contrast to 3-F-BPAP however, the TAAR1 antagonist EPPTB antagonizes the MAE effects of both BPAP and selegiline.
3-F-BPAP has a weak MAE effect itself but with much lower potency than BPAP. The effects of MAEs like BPAP and selegiline appear to be mediated by TAAR1 agonism, and hence 3-F-BPAP may be acting as a TAAR1 antagonist.
3-F-BPAP was developed by József Knoll and colleagues and was first described in the scientific literature in 2002.